Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record and from the shape of the literature, which for this compound is large in a way that misleads.
LL-37 has no list price, no prescription route, no insurance pathway and no manufacturer, because it is not approved anywhere, its one drug programme stopped after a negative Phase 2b, and it sits on the FDA's list of compounding substances that may present significant safety risks with named nonclinical harms.1
This page publishes no prices. What follows is what determines the money.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. For LL-37 the substance is known in extraordinary detail, and nothing else is in place. There is no standard, no indication, and the documented human effects are from a cream on a wound: a positive small trial and a negative larger one.23
Paying for a Literature
LL-37 is the peptide in this library whose price is most clearly a price for its bibliography. Thousands of papers describe its antimicrobial, immune and wound-healing biology, and product pages quote them. Almost none of that work involved giving LL-37 to a person, and the ONPEPS grade, which counts publications and late-stage trials, places the compound at B on the strength of research that is about the molecule rather than about treating anyone with it. A buyer is paying for the impressiveness of what is known, not for evidence that the vial does anything.
Access
Is There a Legal Route?
Not in the United States. LL-37 is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It was placed in the FDA's Category 2 of nominated compounding substances in September 2023 and is now listed as nominated but withdrawn.1 It was not among the peptides considered by the advisory committee in July 2026, so there is no pending recommendation.4
There is no clinical trial to join for any use resembling the marketed ones. The registered studies of LL-37 either measure levels of the body's own peptide or, in the one interventional case still listed, apply a cream to diabetic foot ulcers in Indonesia.5
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. With no approval anywhere there is no covered indication and no billing code attached to one.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, telehealth | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| Bundling into an "immune" or "biofilm" protocol | Clinics, vendors | Other compounds, usually thymosin alpha-1 and KPV, priced together so none is examined alone |
| Length | All channels | A 37-residue peptide genuinely costs more to synthesise than a tripeptide; the premium is real and buys nothing about efficacy |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Raw material of unverified identity and aggregation state, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. It does not buy an aggregation analysis, which for this peptide is the one test that bears on the FDA's stated concern and which no retail certificate provides.
Why Is It Cheaper From a Research Supplier?
Because research suppliers sell genuine reagent to laboratories at reagent prices, with the label meaning what it says. The same vial from a "peptide clinic" costs more because it comes with a protocol and a person. The peptide is not different. The legal exposure and the pretence are.
The Spending Decision
What Result Is Being Paid For?
Immune support, resistance to infection, clearance of biofilm or chronic infection. In humans, LL-37 has been tested for none of those. It has been applied to venous leg ulcers, where a 148-patient trial found no significant benefit over placebo, and to diabetic foot ulcers, where a 40-patient trial found faster granulation on a surrogate measure.36 It has been injected into four melanoma lesions to see what dose could be tolerated.7 It has never been given systemically to anyone.
What the body's own LL-37 does is well established, and that is the source of the confusion. A buyer is reasoning that if the peptide the body makes is protective, more of it, injected, must be more protective. The same logic would apply to cortisol, insulin or histamine, and in each case the body's regulation of the molecule is the point. LL-37 is stored inactive, released locally, and cleared fast, because a systemic excess of it is what sepsis and psoriasis look like.89
The purchase is a bet that a defence peptide the body keeps on a short leash does something good when the leash is removed. No study has tested that bet, and the mechanism argues against it.
What Is the Risk Side of the Ledger?
Named, which is unusual for this list. The FDA's entry states that nonclinical findings "suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues."1 The tumour point is documented across ovarian, lung, breast, prostate, pancreatic and skin cancers and melanoma in laboratory work.10 The autoimmune point follows from the peptide's role as a psoriasis autoantigen and rosacea driver.9 None of this is a measured rate in humans, because nobody has run the study. It is a mechanism with a direction.
What Should Be Asked Before Paying?
Which human study gave LL-37 systemically and measured the outcome you are promising? The honest answer is none.
Are you aware the FDA's entry for this compound names tumour promotion and male reproductive harm, and do you screen for cancer history?1
Can I see a certificate for the batch I will receive, with aggregation and endotoxin results and not only purity?
On what legal basis are you supplying this?
Does anyone here earn commission on product sales?
What Would Change This Page
A Trial, or a Nomination
The large-wound venous ulcer trial the Phase 2b authors called for would change the topical picture; a systemic trial of any design would create a human data point where there is none. A nomination to the FDA's advisory committee would produce a regulator's full reading of the record. None is under way.
A Note on the Grade
ONPEPS grades by published rule from publication and trial counts, and for LL-37 that rule returns B. This page is where the grade is explained: it reflects a vast immunology literature and a set of trials that mostly measure the body's own peptide, not evidence that the product works. A grade is a measure of how much has been written. For this compound, what has been written argues for leaving the peptide where the body keeps it.
Related ONPEPS Coverage
LL-37 library entry: the immunology, the two wound trials and the cancer question
LL-37 sourcing and quality: a 37-residue membrane-active peptide in a vial
Sources
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for cathelicidin LL-37. Content current as of 22 April 2026. fda.gov
Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613-621. Paywalled. pubmed.ncbi.nlm.nih.gov/25041740
Mahlapuu M, Sidorowicz A, Mikosinski J, Krzyżanowski M, Orleanski J, Twardowska-Saucha K, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021;29(6):938-950. Open access. pubmed.ncbi.nlm.nih.gov/34687253
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
ClinicalTrials.gov. Studies listing LL-37 as an intervention. Registry search; checked 16 September 2026. clinicaltrials.gov
Miranda E, Bramono K, Yunir E, Reksodiputro MH, Suwarsa O, Rengganis I, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023;315(9):2623-2633. Paywalled. pubmed.ncbi.nlm.nih.gov/37480520
ClinicalTrials.gov. NCT02225366. Intratumoral Injections of LL37 for Melanoma. Sponsor M.D. Anderson Cancer Center. Phase 1/2, 4 participants, completed. Record retrieved 16 September 2026. clinicaltrials.gov/study/NCT02225366
Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35. Paywalled. pubmed.ncbi.nlm.nih.gov/23246832
Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. Open access. pubmed.ncbi.nlm.nih.gov/25470744
Chen X, Zou X, Qi G, Tang Y, Guo Y, Si J, et al. Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem. 2018;47(3):1060-1073. Open access. pubmed.ncbi.nlm.nih.gov/29843147
Not Medical or Financial Advice
LL-37 is not approved for human use in any jurisdiction and has never been given systemically to a person in a study. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. Re-verify before relying on anything here.